(A–C) Ex vivo frequency of HCV–specific TIGIThigh and TIGITint CD4+ T cells of HCV patients with acute, chronic and spontaneously resolved infection and longitudinally during DAA therapy. (A) Depicting the gating strategy of HCV-specific MHC class II tetramer+ CD4+ T cells divided into subpopulations (TIGIThigh/int/neg) based on the intensity of TIGIT expression and (B) the frequency of TIGIThigh and TIGITint T cells of patients with acute, chronic and spontaneously resolved HCV infection. (C) The TIGIThigh frequency of HCV–specific CD4+ T cells was analysed in longitudinal samples of chronic HCV patients before, during and after DAA therapy. P values were calculated by Tukey’s multiple comparison test. P-values smaller than 0.05 were considered significant, where *,** and *** indicate p-values between 0.01 to 0.05, 0.001 to 0.01 and 0.0001 to 0.001 respectively.